Oncolytic virotherapy with Zika virus in murine glioblastoma
We implanted eight-week-old C57BL/6J mice with CT2A gliomas. On day 7 post-implantation, Zika virus (ZIKV; n=9 mice) or phosphate-buffered saline (PBS; control; n=9 mice) were administered intratumorally. On day 10, 14, and 21 post-implantation (or day 3, 7, and 14 post-ZIKV treatment or PBS saline; n=3 per time point per treatment condition), the gliomas were resected, and immune cells were isolated, sorted, and pooled for single-cell RNA (scRNA-seq) and T cell receptor sequencing (scTCR-seq). As additional controls, cells from naive mice (n=3) as well as mice treated with ZIKV alone on day 3, 7, and 14 post treatment (n=3 per time point), without tumor implantation.